Enrolled 95

Allocated to QD schedule (n=38)Received OSI-906 (n=33)

Discontinued (n=33)Disease progression (n=21)Adverse event (n=7)Medical/ethical reasons (n=1)Patient request (n=4)

Discontinued (n=23)Disease progression (n=17)Adverse event (n=4)Medical/ethical reasons (n=1)Patient request (n=1)

Allocated to BID schedule(n=26)Received OSI-906 (n=24)

Evaluated for:Safety (n=33)DL T (n=27)Pharmacokinetics (n=33)Efficacy (n=24)

Allocated to BID schedule(n=31)Received OSI-906 (n=29)

Evaluated for:Safety (n=22)DL T (n=22)Pharmacokinetics (n=24)Efficacy (n=19)

Discontinued (n=28)Disease progression (n=26)Adverse event (n=2)

Evaluated for:Safety (n=29)Pharmacokinetics (n=29)Efficacy (n=22)

Expansion cohorts* Dose escalation cohorts

Figure 1. Patient disposition. *Including nine patients in the diabetes expansion cohort and twenty patients in the biomarker expansion cohort